GT Biopharma (NASDAQ:GTBP) Shares Set to Reverse Split on Tuesday, September 8th

Shares of GT Biopharma, Inc. (NASDAQ:GTBP) are set to reverse split on Tuesday, September 8th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, September 7th.

GT Biopharma Price Performance

Shares of GT Biopharma stock traded down $0.01 during trading on Friday, reaching $0.24. 1,158,788 shares of the company traded hands, compared to its average volume of 1,121,215. The firm has a market capitalization of $10.87 million, a PE ratio of -0.04 and a beta of 0.91. GT Biopharma has a 1-year low of $0.22 and a 1-year high of $1.37. The company has a 50 day moving average price of $0.34 and a 200-day moving average price of $0.39.

GT Biopharma (NASDAQ:GTBP) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). Equities research analysts expect that GT Biopharma will post -0.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on GTBP. Wall Street Zen raised GT Biopharma to a “hold” rating in a research report on Saturday, June 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of GT Biopharma in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, GT Biopharma currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On GT Biopharma

An institutional investor recently bought a new position in GT Biopharma stock. 49 Wealth Management LLC bought a new position in GT Biopharma, Inc. (NASDAQ:GTBP) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 64,000 shares of the company’s stock, valued at approximately $31,000. 49 Wealth Management LLC owned about 0.14% of GT Biopharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.15% of the company’s stock.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).